Form 4: Neogenomics Executive Adjusts Holdings
Statement of Changes in Beneficial Ownership
Neogenomics Inc. reports changes in beneficial ownership for its President & Chief Operating Officer, Warren Stone, involving stock options and restricted stock units.
Summary
- Warren Stone, President & Chief Operating Officer of Neogenomics Inc., has reported transactions related to his beneficial ownership of company securities.
- These transactions include the acquisition of restricted stock units and the disposal of common stock.
- The filing details various stock options, restricted stock units, and performance stock units granted to Mr. Stone, with specific vesting schedules and exercise prices.
- Notable events include modifications to vesting schedules for certain stock options and restricted stock units in connection with his promotion to President & Chief Operating Officer on April 1, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting routine changes in beneficial ownership and executive compensation structures without significant positive or negative financial disclosures.
Positives
- Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, indicates internal advancement and recognition.
- The modification of vesting schedules for stock options and restricted stock units upon promotion suggests continued commitment and incentive alignment.
- A significant number of stock options and restricted stock units are held, indicating substantial equity participation.
Negatives
- The disposal of 6,911 shares of common stock on April 1, 2026, represents a reduction in direct ownership.
Risks
- Vesting schedules for performance stock units are contingent on achieving certain growth goals, including weighted average stock price and revenue growth, which introduces performance-based risk.
- Premium-price stock options have exercise prices set above the market price at the time of grant, which could impact their value if the stock price does not appreciate sufficiently.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance. However, the details of stock options and performance stock units with future vesting and performance criteria imply a long-term outlook tied to company performance and stock appreciation.
Management Comments
- The modification of vesting schedules for certain stock options and restricted stock units in connection with Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, indicates a strategic alignment of executive incentives with company growth and leadership.
- The structure of performance stock units, tied to weighted average stock price and revenue growth goals, suggests a focus on achieving specific financial and market performance targets.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock. The details provided by Neogenomics Inc. regarding stock options and restricted stock units are typical for executive compensation packages in the biotechnology and diagnostics sector, aiming to align executive interests with shareholder value.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | Warren Stone | 04/01/2025 | Promotion |
Stakeholder Impact
- Shareholders: The filing provides transparency into executive compensation and equity holdings, which can influence investor perception of management alignment and long-term strategy.
- Employees: The structure of executive compensation, including stock-based awards, can set a precedent or benchmark for employee incentive programs.
- Management: The filing details the equity interests and compensation of a key executive, Warren Stone.
Next Steps
- Continued vesting of stock options and restricted stock units according to their respective schedules.
- Achievement of performance criteria for performance stock units to vest.
- Potential exercise of vested stock options.
- Ongoing reporting of any future changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2026 | Earliest transaction date reported and date of acquisition of 17,562 common stock units and disposal of 6,911 common stock units. |
| 04/01/2025 | Effective date of promotion to President & Chief Operating Officer, leading to modification of vesting schedules for certain stock options and restricted stock units. |
| 02/21/2025 | Grant date for 143,266 stock options and 84,317 restricted stock units, with subsequent vesting schedule modification. |
| 04/01/2025 | Grant date for 52,687 restricted stock units, with a vesting schedule. |
| 02/20/2025 | Date used to calculate the premium exercise price for a specific stock option grant. |
| 01/13/2026 | Grant date for restricted stock units. |
| 05/02/2024 | Grant date for 29,976 stock options and 17,908 performance stock units, and 17,905 restricted stock units. |
| 02/23/2024 | Grant date for 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units. |
| 05/11/2023 | Grant date for 53,969 stock options, 21,204 performance stock units, and 28,838 restricted stock units. |
| 12/01/2022 | Grant date for 166,113 stock options. |
| 03/01/2026 | Grant date for 253,378 stock options and 152,594 restricted stock units. |
| 04/01/2025 | Grant date for 94,518 stock options. |
| 02/27/2026 | Date used to calculate the premium exercise price for a specific stock option grant. |
Keywords
Form 4, Neogenomics Inc., Warren Stone, Beneficial Ownership, Stock Options, Restricted Stock Units, Performance Stock Units, Insider Trading, SEC Filing, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.